Analysis – Goldea Capital

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Written by Customer Service on August 6, 2026. Posted in Mergers And Acquisitions.

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the largest inherited retinal diseases with no FDA-approved therapy 400+ individuals treated to date, with encouraging positive structural and functional clinical findings; and over seven years of long-term tolerability data Top-line Phase 3 NORTHSTAR data expected in the second half of 2029; Has received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations Together with IRX-101, this acquisition is expected to expand Tarsus’ presence in retina and further strengthen one of the most compelling pipelines in eye care Management to host conference call today, August 6, 2026, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., Aug....

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Written by Customer Service on August 6, 2026. Posted in Mergers And Acquisitions.

NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries. This acquisition expands Harrow’s dry eye portfolio, complementing the Company’s flagship VEVYE franchise by addressing dry eye disease with a different underlying mechanism of action. Together, VEVYE and TYRVAYA enable Harrow to provide physicians with a broader...

OpenFX Acquires Global Ledger to Launch Multi-Currency Accounts for Fintechs

Written by Customer Service on August 6, 2026. Posted in Mergers And Acquisitions.

Novo co-founder Tyler McIntyre joins as Head of Banking; OpenFX will be launching a waitlist for their multi-currency accounts product, the first one hundred companies to join the waitlist receive $30,000 in fee creditsOpenFX Launches Multi-Currency Accounts For FintechsOpenFX is launching multi-currency accounts for fintechs: collect USD locally and pay out over ACH, Fedwire, SWIFT or stablecoin rails. Request early access.MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) — OpenFX, the real-time cross-border money movement platform, announced today that it has acquired Global Ledger, founded by Tyler McIntyre. McIntyre previously built and co-founded Novo, a neo-bank serving >300,000 business last valued at over $700M. McIntyre is joining as Head of Banking to accelerate OpenFX’s product expansion and launch multi-currency accounts,...

Sunrise Realty Trust, Inc. and Southern Realty Trust Inc. Announce Definitive Merger Agreement

Written by Customer Service on August 6, 2026. Posted in Mergers And Acquisitions.

Merger Would Consolidate Two Transitional CRE Lenders Focused on the Southern U.S. Into a Single Public Company Combination Expected to Enhance Stockholder Value Through Increased Margin, Broader Index Inclusion, Improved Trading Liquidity, and Access to More Efficient LeveragePro Forma Loan Commitments as of June 30, 2026 Pro Forma Total Assets as of June 30, 2026 Potential Annual G&A Savings on a Combined Basis Expected Reduction in Incentive Fee and Hurdle Rate Under SUNS Management Agreement Enhanced Earnings Potential$604 million $534 million Anticipated Increase in Margin 20% → 17.5% (incentive fee) 8% → 7% (hurdle rate) Increase in Equity Base with Lower Expenses on a Combined BasisThe merger would combine two complementary commercial real estate lending portfolios managed under a common investment philosophy and is...

Americold Announces Second Quarter 2026 Results

Written by Customer Service on August 6, 2026. Posted in Earnings Releases And Operating Results.

Delivered $0.35 Adjusted FFO Per Share and Raises Full-Year Guidance Year-Over-Year Revenue and Occupancy Growth Reflect Continued Industry Stabilization Advanced Strategic Joint Venture to Strengthen Balance Sheet and Enhance Financial Flexibility ATLANTA, Aug. 06, 2026 (GLOBE NEWSWIRE) — Americold Realty Trust, Inc. (NYSE: COLD) (the “Company”), a global leader in temperature-controlled logistics, ensuring safe, efficient food movement worldwide, today announced financial and operating results for the second quarter ended June 30, 2026. “Americold delivered another quarter of strong results, with Adjusted FFO of $0.35 per share exceeding our expectations and total revenues increasing year-over-year. We were encouraged by ongoing growth in both physical occupancy and pricing, as industry fundamentals show continued signs...

Knight Therapeutics Reports Second Quarter 2026 Results

Written by Customer Service on August 6, 2026. Posted in Earnings Releases And Operating Results.

Increased 2026 guidance and expect revenues of $540 million to $560 millionAchieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million MONTREAL, Aug. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) pharmaceutical company, today reported financial results for its second quarter ended June 30, 2026. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q2-26 Highlights Financial Results – IFRSRevenues were $144,212, an increase of $36,854 or 34% over the same period in the prior year. The increase was primarily driven by the growth of our promoted products, incremental revenues from mature products added from the Paladin and Sumitomo transactions,...

Aspen Aerogels, Inc. Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Written by Customer Service on August 6, 2026. Posted in Earnings Releases And Operating Results.

Q2 2026 Thermal Barrier revenue of $29.5 million, up 81% quarter-over-quarterQ3 2026 expected revenue range of $65 to $80 million and adjusted EBITDA range of $7 to $15 millionEuropean Thermal Barrier 2026 revenue outlook raised to $20 to $30 millionPyroThin® award from Jaguar Land Rover for two next-generation vehicle architectures NORTHBOROUGH, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) — Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the “Company”), a technology leader in sustainability and electrification solutions, today announced financial results for the second quarter of 2026, and discussed recent business developments. Second Quarter 2026 Results Total revenue for the second quarter of 2026 was $49.8 million, compared to $78.0 million in the prior year period. Thermal Barrier segment revenue was $29.5 million, compared to $55.2...

Teads Holding Co. Announces Second Quarter 2026 Results

Written by Customer Service on August 6, 2026. Posted in Earnings Releases And Operating Results.

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) — Teads Holding Co. (Nasdaq: TEAD) (“Teads” or the “Company”) announced today financial results for the quarter ended June 30, 2026. Second Quarter 2026 Key Financial Metrics: Three Months EndedJune 30, Six Months EndedJune 30,(in millions USD) 2026 2025 % Change 2026 20251 % ChangeRevenue $ 284.6 $ 343.1 (17 )% $ 550.6 $ 629.5 (13 )%Gross profit 95.6 120.3 (21 )% 179.2 202.9 (12 )%Net loss (42.5 ) (14.3 ) (197 )% (81.3 ) (69.2 ) (17 )%Net cash provided by (used in) operating activities 9.2 25.0 (63 )% (25.7 ) 24.1 (207 )% Non-GAAP Financial Data* Ex-TAC gross profit 123.4 144.2 (14 )% 231.3 247.3 (6 )%Adjusted...

More Americans Have Access to Credit While Debt Growth Has Moderated

Written by Customer Service on August 6, 2026. Posted in Public Companies.

Q2 2026 TransUnion Credit Industry Insights Report shows balance growth, broader access and measured monthly payment pressure CHICAGO, Aug. 06, 2026 (GLOBE NEWSWIRE) — New TransUnion (NYSE: TRU) research finds that consumer credit remains widely available despite economic uncertainty, while credit usage continues to grow at a pace largely consistent with inflation. TransUnion released the findings in conjunction with its Q2 2026 Credit Industry Insights Report (CIIR). Consumer access to credit continued to expand in Q2 2026, with just under 262 million consumers carrying a credit balance. Total outstanding balances also grew steadily, reflecting broader credit participation and borrowing patterns consistent with recent years. “This continued expansion in credit access shows that lenders are still extending credit broadly across...

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Written by Customer Service on August 6, 2026. Posted in Public Companies.

People with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social well-being Study results informed the design and endpoint selection of the ongoing Phase 3 CREAATE studyZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from the first in-depth qualitative study assessing the experiences of people with AAE-C1INH and validating relevant patient-reported outcome (PRO) measures have been published in Frontiers in Immunology....

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals